<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01569802</url>
  </required_header>
  <id_info>
    <org_study_id>11-02</org_study_id>
    <nct_id>NCT01569802</nct_id>
  </id_info>
  <brief_title>A Comparison of Recall Rates Between Conventional 2d Mammography and 2d Plus 3d (Tomosynthesis) Mammography in a Screening Population</brief_title>
  <official_title>A Comparison of Recall Rates Between Conventional 2d Mammography and 2d Plus 3d (Tomosynthesis) Mammography in a Screening Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rose Imaging Specialists, P.A.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hologic, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Rose Imaging Specialists, P.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary aim of this study is to measure, document and compare recall rates of
      two-dimensional plus three dimensional (2D plus 3D) (Tomosynthesis) mammography to that of 2D
      mammography in a screening population. This study will compare recall rates for both
      non-cancer and cancer cases.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2012</start_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Recall Rate</measure>
    <time_frame>up to 1 year</time_frame>
    <description>measure, document and compare recall rates of two-dimensional plus three dimensional (2D plus 3D) (Tomosynthesis) mammography to that of 2D mammography in a screening population</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cancer detection Rate</measure>
    <time_frame>up to 1 year</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">10000</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>screening</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        radiology clinic screening population
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is female of any race and ethnicity

          -  The subject is asymptomatic and presents for routine screening mammography and chooses
             to have a combination 2D + 3D mammogram as her standard of care.

        Exclusion Criteria:

          -  Patient chooses standard 2D mammography over a combination 2D + 3D mammogram
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>TOPS</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77090</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andra Tidwell, RT(R)(M)</last_name>
      <phone>281-580-6171</phone>
      <email>atidwell@uspi.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 29, 2012</study_first_submitted>
  <study_first_submitted_qc>March 30, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 3, 2012</study_first_posted>
  <last_update_submitted>March 30, 2012</last_update_submitted>
  <last_update_submitted_qc>March 30, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 3, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>breast cancer screening</keyword>
  <keyword>tomosynthesis</keyword>
  <keyword>FFDM</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

